Developing a new antibiotic to treat drug-resistant tuberculosis
Teixobactin Development for Tuberculosis
This study is looking at a new medicine called teixobactin that could help people with drug-resistant tuberculosis (TB) by offering a safer and shorter treatment that has fewer side effects and helps prevent the bacteria from becoming resistant.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Novobiotic Pharmaceuticals, LLC NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10878819 on NIH RePORTER |
What this research studies
This research focuses on the development of teixobactin (TXB) as a potential treatment for drug-resistant tuberculosis (TB). TB is a significant global health threat, and many patients struggle with lengthy treatment regimens that can lead to drug resistance. The study aims to create a safer and shorter treatment option that minimizes side effects and avoids the development of resistance. TXB works by targeting specific components of the bacterial cell wall, making it difficult for the bacteria to adapt and survive.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with drug-resistant tuberculosis who have not responded to standard treatments.
Not a fit: Patients with drug-sensitive tuberculosis or those who do not have tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and shorter treatment option for patients suffering from drug-resistant tuberculosis.
How similar studies have performed: Previous studies, including one at Johns Hopkins University, have shown promising results for teixobactin in treating tuberculosis, indicating potential for success in this research.
Where this research is happening
Cambridge, United States
- Novobiotic Pharmaceuticals, LLC — Cambridge, United States (Active)
Researchers
- Principal investigator: Hughes, Dallas — Novobiotic Pharmaceuticals, LLC
- Study coordinator: Hughes, Dallas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.